Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation

Yong-nan FU#, Han XIAO#, Xiao-wei MA, Sheng-yang JIANG, Ming XU, You-yi ZHANG*

Institute of Vascular Medicine, Peking University Third Hospital and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing 100191, China

Aim: To identify the role of metformin in cardiac hypertrophy and investigate the possible mechanism underlying this effect.

Methods: Wild type and AMPKα2 knockout (AMPKα2–/–) littermates were subjected to left ventricular pressure overload caused by transverse aortic constriction. After administration of metformin (200 mg·kg⁻¹·d⁻¹) for 6 weeks, the degree of cardiac hypertrophy was evaluated using echocardiography and anatomic and histological methods. The antihypertrophic mechanism of metformin was analyzed using Western blotting.

Results: Metformin significantly attenuated cardiac hypertrophy induced by pressure overload in wild type mice, but the antihypertrophic actions of metformin were ablated in AMPKα2–/– mice. Furthermore, metformin suppressed the phosphorylation of Akt/protein kinase B (AKT) and mammalian target of rapamycin (mTOR) in response to pressure overload in wild type mice, but not in AMPKα2–/– mice.

Conclusion: Long-term administration of metformin may attenuate cardiac hypertrophy induced by pressure overload in nondiabetic mice, and this attenuation is highly dependent on AMPK activation. These findings may provide a potential therapy for patients at risk of developing pathological cardiac hypertrophy.

Keywords: metformin; cardiac hypertrophy; AMP-activated protein kinase; protein synthesis; transverse aortic constriction; Akt/protein kinase B; mammalian target of rapamycin

Introduction

Metformin is one of the most commonly prescribed antihyperglycemic drugs for the treatment of type 2 diabetes that does not cause hypoglycemia. Apart from its antihyperglycemic effect, metformin has been believed to have other potential effects, as indicated in two large-scale clinical trials [1, 2]. Those trials suggested that metformin could significantly decrease the risk of diabetes-related cardiovascular end points and all cause deaths compared with conventional therapies when lowering blood glucose to similar levels. However, the exact mechanism associated with the cardioprotective role of metformin is still elusive.

AMPK is a serine-threonine kinase that acts as an energy sensor in various cell types [3]. It also plays an important role in cardioprotective effects [4, 5]. Zhou et al [6] demonstrated that metformin could activate AMPK. Recent studies have suggested that metformin could inhibit cardiomyocyte apoptosis and improve cardiac function through AMPK activation [7, 8]. Pathological left ventricular hypertrophy is a crucial pathological condition that triggers several serious cardiac events, including arrhythmias, heart failure, and sudden death [9, 10]. However, whether metformin has an inhibitory effect on cardiac hypertrophy has not been elucidated. Thus, we hypothesized that metformin might have a direct antihypertrophic effect via AMPK activation.

In this study, we aim to determine whether metformin inhibits cardiac hypertrophy induced by pressure overload and how metformin exerts its antihypertrophic effect.

Materials and methods

Animals

The research protocol was designed in compliance with the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health of the United States of America (NIH Publication No. 85-23, revised 1996). All experimental protocols were approved by the Institutional Committee for Animal Care and Use of Peking University. Heterozygous
AMPKα2 knockout C57BL/6 mice were kindly donated by Professor Benoit VIOLLET (Institute National de la Santé et de la Recherche Médicale U567, Paris, France) and bred in an specific pathogen free (SPF) environment with a 12 h/12 h light-dark cycle and received standard rodent food. Male AMPKα2+/− mice and wild-type (WT) littermates (10 weeks old) were bred from the heterozygotes.

TAC and drug treatment

Transverse aortic constriction (TAC) was carried out as previously described[11]. Briefly, the mice were anesthetized with tribromoethanol (200 mg/kg, ip; Sigma-Aldrich, Milwaukee, WI, USA) and ventilated with a pressure-controlled ventilator (Kent Scientific, CT, USA). A longitudinal cut was made in the proximal portion of the sternum. A 7–0 silk suture was placed around the aorta between the right innominate artery and the left common carotid artery. The suture was tied around a 26-gauge needle and the aorta. After ligation, the needle was promptly removed. The sham procedure was identical, except the aorta was not ligated. Three days after aortic constriction, the mice were injected with metformin (200 mg·kg⁻¹·d⁻¹, sc, Sigma-Aldrich, St Louis, MO, USA) or saline (as a control) every day for 6 weeks.

Echocardiography and evaluation of left ventricular (LV) hemodynamics

After anesthetizing the mice with 1.5% isoﬂurane (Baxter Healthcare Corporation, New Providence, NJ, USA), we obtained echocardiographic images with a VisualSonics high-resolution Vevo 770 system (VisualSonics, Toronto, ON, Canada). For measurement of the aortic and LV pressure, a 1.4-F micromanometer conductance catheter (SPR-835; Millar Instruments, Houston, TX, USA) was introduced through the right common carotid artery into the ascending aorta and then advanced into the LV as previously described[12].

Histological analysis

The mice were anesthetized with tribromoethanol, and the hearts were harvested, retrograde-perfused with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde overnight, and then embedded in paraffin. Serial 6-μm-thick LV cross sections were stained with hematoxylin and eosin (HE). Morphometric evaluation of the tissue was performed in a blinded fashion using the Leica Q550 IW imaging workstation (Leica Microsystems Imaging Solutions Ltd, Cambridge, UK). The mean myocyte cross-sectional area was calculated by measuring 100 cells in the HE-stained sections.

Quantitative real-time PCR

Total RNA was isolated from the heart tissue with Trizol Reagent (Invitrogen, Carlsbad, CA, USA). Relative quantification by real-time PCR involved SYBR Green detection of PCR products in real time with the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). The PCR used the following primers: atrial natriuretic factor (ANF), 5′-GCCCTGACGTCGACTG-3′ (forward) and 5′-CG-GAACGTGTGCAGCCTA-3′ (reverse); β-myosin heavy chain (β-MHC), 5′-ACCTAC CAGACAGGAAGA-3′ (forward) and 5′-TGCAAGAGTCAGGTTGCG-3′ (reverse); and GAPDH, 5′-CTCTGGATGACAAATGATCCGG-3′ (forward) and 5′-TCTGCTAGTGTCCTTGTGG-3′ (reverse). The GAPDH RNA was amplified as a reference standard. The reactions were conducted in triplicate by heating the reactant to 95 °C for 5 min, followed by 40 cycles of 94 °C for 30 s, 58 °C for 30 s and 72 °C for 30 s.

Western blot analysis

The heart extracts were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and blotted on nitrocellulose membranes. The membranes were incubated with antibodies against phosphorylated AMPK, acetyl CoA carboxylase (ACC), eukaryotic elongation factor-2 (eEF2), mammalian target of rapamycin (mTOR) and Akt/protein kinase B (AKT) and then against the respective total level of each protein (antibodies from Cell Signaling Technology Incorporated, Danvers, MA, USA). The protein bands were visualized with Supersignal West Dura Extended Duration Substrate (Thermo Fisher Scientific, Rockford, IL, USA). The blots were subsequently reprobed with the antibody eIF5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) to confirm equal loading.

Statistical analysis

The data are expressed as the means±SEM. Intergroup comparisons were performed using Prism 4 (GraphPad Software Incorporate, La Jolla, CA, USA) with Student’s paired two-tailed t-test or two-way ANOVA. For the ANOVA, if a significant variance was found, the Tukey or Bonferroni test was used as the post hoc analysis. P<0.05 was considered statistically significant.

Results

Metformin attenuates cardiac hypertrophy induced by TAC in WT mice

To determine whether metformin plays a part in cardiac hypertrophy induced by TAC, we treated TAC-operated mice with metformin (200 mg·kg⁻¹·d⁻¹) or saline for 6 weeks after surgery. Echocardiographic data showed no significant difference in the WT mice before sham or TAC operation (data not shown). The mice that received TAC developed cardiac hypertrophy with normal cardiac systolic function 6 weeks after the operation (Figure 1, Table 1). Sustained treatment with metformin decreased the LV posterior wall dimension in diastole (LVPWd) compared with saline-treated hearts (Figure 1A, 1B). The heart weight/tibial length (HW/TL) of the TAC+saline group increased by only 11.7% compared with the sham+saline group (P<0.01; Figure 1C). In contrast, the HW/TL of the TAC+metformin group increased by 26% compared with the sham+saline group (P<0.01; Figure 1C). The heart weight/tibial length (HW/TL) of the TAC+metformin group increased by 26% compared with the sham+saline group. It could therefore be calculated that metformin suppressed the TAC-induced increase in HW/TL by 55% (P<0.05; Figure 1C). The cardiomyocyte cross-sectional area also decreased in the metformin-treated
Similar to what was observed in WT mice, TAC induced groups, c

|                | Saline | Metformin | Saline | Metformin | Saline | Metformin | Saline | Metformin |
|----------------|--------|-----------|--------|-----------|--------|-----------|--------|-----------|
| n              | 9      | 8         | 9      | 8         | 9      | 8         | 9      | 8         |
| Body weight (g) | 25.9±0.96 | 25.3±1.02 | 27.0±1.03 | 25.0±0.75 | 26.1±0.82 | 27.0±0.99 | 27.6±0.78 | 26.7±0.80 |
| Heart weight (mg) | 114.1±3.7 | 109.4±4.4 | 150.0±7.2 | 126.4±4.9 | 117.5±3.4 | 112.8±4.7 | 152.5±5.7 | 158.2±6.3  |
| HW/BW (mg/g)   | 4.42±0.07 | 4.31±0.09 | 5.59±0.18 | 5.04±0.13 | 4.47±0.14 | 4.18±0.05 | 5.62±0.17 | 5.9±0.25   |

Echocardiographic data

|                | Saline | Metformin | Saline | Metformin | Saline | Metformin | Saline | Metformin |
|----------------|--------|-----------|--------|-----------|--------|-----------|--------|-----------|
| n              | 9      | 8         | 9      | 8         | 9      | 8         | 9      | 8         |
| HR (bpm)       | 408±8  | 440±12    | 421±15 | 431±19    | 425±11 | 411±10    | 447±17 | 428±10    |
| LVIDd (mm)     | 4.02±0.10 | 3.93±0.13 | 4.14±0.11 | 3.79±0.10 | 3.92±0.09 | 3.91±0.12 | 4.04±0.11 | 4.16±0.08 |
| LVIDs (mm)     | 2.79±0.13 | 2.62±0.17 | 3.02±0.15 | 2.60±0.11 | 2.61±0.12 | 2.66±0.13 | 2.91±0.14 | 3.01±0.14 |
| LVAWd (mm)     | 0.82±0.03 | 0.76±0.02 | 1.02±0.03 | 0.89±0.02 | 0.83±0.03 | 0.80±0.02 | 1.07±0.05 | 1.08±0.05  |
| FS%            | 31.0±1.76 | 35.3±2.53 | 31.7±1.08 | 32.9±1.29 | 32.8±1.55 | 32.1±1.95 | 29.8±1.54 | 30.7±1.22  |

Hemodynamic data

|                | Saline | Metformin | Saline | Metformin | Saline | Metformin | Saline | Metformin |
|----------------|--------|-----------|--------|-----------|--------|-----------|--------|-----------|
| n              | 9      | 8         | 9      | 8         | 9      | 8         | 9      | 8         |
| HR (bpm)       | 479±15 | 475±26    | 491±29 | 474±20    | 493±18 | 479±19    | 494±21 | 471.6±16  |
| Systolic BP (mmHg) | 81.2±5.4 | 82.8±2.4 | 127.5±7.0 | 124.2±9.2 | 89.5±2.5 | 91.4±4.1 | 131.7±8.3 | 133.1±7.1 |
| Diastolic BP (mmHg) | 55.0±4.5 | 57.7±3.5 | 67.9±6.9 | 61.3±5.5 | 57.4±3.1 | 62.5±5.8 | 70.9±4.9 | 66.3±4.6  |
| LVSP (mmHg)    | 81.8±4.1 | 83.6±3.4 | 132.8±6.7 | 130.8±8.1 | 91.4±3.0 | 92.3±5.2 | 132.5±8.8 | 135.7±5.5 |
| LVEDP (mmHg)   | 1.2±0.8 | 1.9±1.3  | 8.7±1.0 | 5.2±1.5 | 2.0±1.0 | 2.5±0.8 | 9.9±1.6 | 7.8±1.4   |
| +dp/dt (mmHg/s) | 841.4±51.4 | 7318±435 | 8259±679 | 7548±790 | 8619±543 | 8618±651 | 8977±755 | 7892±328  |
| -dp/dt (mmHg/s) | -7973±364 | -7124±286 | -8498±673 | -8657±471 | -8582±303 | -7928±306 | -8720±768 | -7190±753 |

To investigate whether AMPK was critical for the inhibitory effect of metformin on cardiac hypertrophy, we subjected AMPKα2−/− littermates to pressure overload caused by TAC. Similar to what was observed in WT mice, TAC induced cardiac hypertrophy without deteriorating cardiac systolic function. However, sustained treatment with metformin did not decrease the LVPWd compared with saline-treated hearts (Figure 2A, 2B). The HW/TL did not decrease in the TAC+metformin group compared with the TAC+saline group (Figure 2C, Table 1). The cardiomyocyte cross-sectional area was similar in the TAC+metformin group and the TAC+saline group (Figure 2D, 2E). Echocardiographic and hemodynamic data showed that sustained metformin treatment did not affect cardiac systolic function (Table 1). Contrary to the findings in WT mice, metformin did not improve diastolic function that was impaired by TAC (P<0.05, Table 1). Moreover, metformin treatment in the AMPKα2−/− littermates did not inhibit the TAC-induced increase in mRNA levels of ANF and β-MHC (Figure 1F, 1G). Taken together, these results indicate that metformin attenuated the development of TAC-induced cardiac hypertrophy independent of hemodynamics. Morever, there was no significant difference in anatomic and functional data (Table 1) between the sham+saline group and the sham+metformin group; therefore, metformin did not affect normal cardiac structure or function.

**Metformin does not attenuate cardiac hypertrophy induced by TAC in AMPKα2−/− mice**

To investigate whether AMPK was critical for the inhibitory effect of metformin on cardiac hypertrophy, we subjected AMPKα2−/− littermates to pressure overload caused by TAC. Similar to what was observed in WT mice, TAC induced cardiac hypertrophy without deteriorating cardiac systolic function. However, sustained treatment with metformin did not decrease the LVPWd compared with saline-treated hearts (Figure 2A, 2B). The HW/TL did not decrease in the TAC+metformin group compared with the TAC+saline group (Figure 2C, Table 1). The cardiomyocyte cross-sectional area was similar in the TAC+metformin group and the TAC+saline group (Figure 2D, 2E). Echocardiographic and hemodynamic data showed that sustained metformin treatment did not affect cardiac systolic function (Table 1). Contrary to the findings in WT mice, metformin did not improve diastolic function that was impaired by TAC (P>0.05, Table 1). Moreover, metformin treatment in the AMPKα2−/− littermates did not inhibit the TAC-induced increase in mRNA levels of ANF and β-MHC (Figure 2F, 2G). It can therefore be concluded that the inhibitory effect of metformin on cardiac hypertrophy is dependent on AMPK.

We also measured the postoperative level of fasting blood glucose every week for 6 weeks in each group. There was no significant difference in the fasting blood glucose between saline- and metformin-treated mice (data not shown). These results suggest that metformin did not affect the level of fasting blood glucose in nondiabetic mice.
Effect of metformin on AMPK phosphorylation and protein synthesis.

To examine the role of AMPK in the antihypertrophic action of metformin, we assessed the extent of phosphorylated AMPK in WT mouse hearts. There was a significant increase in the phosphorylation of AMPK at threonine residue 172 in the metformin-treated group compared with the saline-treated group ($P<0.05$; Figure 3). Metformin treatment also increased the amount of phosphorylated acetyl coenzyme A (CoA) carboxylase (p-ACC), which serves as an indicator of AMPK activity.
Total myocardial AMPKα and phosphorylated AMPKα were significantly decreased in AMPKα2−/− mice, both under control conditions and after TAC, compared with the WT mice (Figure 4). After TAC for 6 weeks, the increase in total AMPKα protein indicated a compensatory increase in AMPKα1 in AMPKα2−/− mice, yet it was unable to compensate for the AMPKα2 deficiency, as demonstrated by significantly lower levels of p-ACC (Figure 4).

LVH is characterized by an increased myocardial cell size in which protein synthesis is a necessary mediator. mTOR,
AKT, and eEF2 all play essential roles in the process of protein synthesis and cell growth. Western blot analysis showed a significant increase in phosphorylated mTOR and AKT in the TAC+saline group, but this increase was significantly inhibited in the TAC+metformin group ($P < 0.05$; Figure 5A, 5B). However, the phosphorylation level of eEF2 did not show a significant change in any of the groups (Figure 5).

Next we tested the phosphorylation level of these proteins in AMPKα2−/− mice hearts. Similar to the effect in WT mice, TAC induced a significant increase in phosphorylated mTOR and AKT ($P < 0.05$; Figure 5A, 5C). Interestingly, metformin did not inhibit the TAC-induced increase of phosphorylated mTOR and AKT in AMPKα2−/− mice (Figure 5A, 5C), suggesting that the inhibitory effect of metformin on protein synthesis may rely on AMPK.

**Discussion**

This study demonstrated that long-term (6 weeks) administration of metformin, a widely used antidiabetic agent, attenuated pressure-overload-induced cardiac hypertrophy in nondiabetic mice, and the mechanism of this antihypertrophic action was dependent on AMPK activation.

Chan et al. have shown that metformin inhibits cardiomyocyte hypertrophy induced by phenylephrine. However, it is still unclear whether metformin has an inhibitory effect on cardiac hypertrophy in vivo and what dose is necessary for this inhibitory effect, if it exists. In this study, we used a cardiac hypertrophy mouse model in which cardiac hypertrophy without systolic dysfunction was induced by treatment with TAC for 6 weeks. Metformin treatment (200 mg·kg−1·d−1) was found to significantly alleviate the cardiac hypertrophy induced by TAC. In the preliminary examination, we also tested metformin at a dosage of 50 mg·kg−1·d−1 in the wild type mice and found that this dosage of metformin had no significant effect on cardiac hypertrophy (data not shown). Although the dose of metformin we used in this study is higher than that used in diabetes patients (10–40 mg/kg), previous reports investigating the anti-diabetic and anti-tumor effects of metformin in the mouse model used a much higher amount of metformin (250–350 mg/kg) due to the difference in drug sensitivity between rodents and humans. The dosage of 200 mg·kg−1·d−1 that we used in this study was effective on hypertrophy and had no side effect of hypoglycemia. Thus, we believe that the dose of 200 mg·kg−1·d−1 is appropriate.

To demonstrate that metformin has a direct inhibitory effect on cardiac hypertrophy rather than a secondary effect due to lowering pressure overload, we measured the aortic and LV pressure in each group. TAC mice had a marked increase in the SBP and LVSP ($P < 0.001$; Table 1) compared with sham-operated mice. There was no significant difference in the SBP or LVSP (Table 1) between the TAC+saline and the TAC+metformin group. Our study indicated that metformin did not affect pressure overload, and it had a direct inhibitory effect on cardiac hypertrophy. Similarly, a clinical trial also suggested that metformin had only a clinically insignificant effect on cardiac hypertrophy.
effect on blood pressure in non-diabetic hypertensives\textsuperscript{[17]}. We previously reported that metformin inhibited cardiac fibrosis in the TAC-mouse model and demonstrated that it inhibited collagen synthesis, likely via inhibition of the TGF-β\textsubscript{1}-Smad3 signaling pathway\textsuperscript{[18]}. Some studies have suggested an important role for TGF-β\textsubscript{1} in regulating cardiac hypertrophy. Transgenic mice overexpressing TGF-β\textsubscript{1} have been shown to develop cardiac hypertrophy\textsuperscript{[19]}. Conversely, wild-type mice, but not TGF-β\textsubscript{1}-deficient mice, treated chronically with angiotensin II manifested cardiac hypertrophy\textsuperscript{[20]}. However, the effect of TGF-β\textsubscript{1} signaling on TAC-induced cardiac hypertrophy is still not fully understood. Some studies have shown that a change in the TGF-β signaling pathway did not affect TAC-induced cardiac hypertrophy. Kuwahara et al\textsuperscript{[21]} found that an anti-TGF-β neutralizing antibody inhibited myocardial fibrosis, but not myocyte hypertrophy. Another study also found that candesartan (an ACE inhibitor) suppressed the induction of TGF-β and fibroblast proliferation in pressure-overloaded hearts, but did not affect myocyte hypertrophy\textsuperscript{[22]}. In this study, we focused on AMPK signaling cascades, and we did not investigate whether the TGF-β\textsubscript{1}-Smad3 signaling pathway was involved in the metformin mediated anti-hypertrophic effect.

The inhibitory effect of metformin on cardiac hypertrophy via AMPK activation

Many studies have recently suggested that the cardioprotective mechanism of metformin is mediated by AMPK. Metformin protects the heart against ischemia-reperfusion injury through AMPK activation\textsuperscript{[7]}. Sasaki et al\textsuperscript{[8]} demonstrated that metformin inhibited cardiomyocyte apoptosis induced by H\textsubscript{2}O\textsubscript{2} and prevented the progression of heart failure in dogs with the activation of AMPK. Tian et al\textsuperscript{[23]} reported that the activity of AMPK was increased in rat hearts 12 weeks after TAC operation. Zhang et al\textsuperscript{[24]} found that AMPKα2 deficiency exacerbated pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Those findings indicate that AMPKα2 exerts a cardiac protective effect against ventricular hypertrophy and dysfunction triggered by pressure overload. In this study, we found that long-term metformin treatment significantly increased the phosphorylation of AMPK and attenuated cardiac hypertrophy induced by TAC. Interestingly, the antihypertrophic actions of metformin were ablated in AMPKα2\textsuperscript{−/−} mice. These results suggest that the chronic activation of AMPK during the development of cardiac hypertrophy is a critical mechanism that mediates the beneficial actions of metformin.

Although our data demonstrated that AMPKα2 had a cardiac antihypertrophic effect in TAC-operated mice, we did not find a significant increase in the phosphorylation of AMPK in the TAC+saline group compared with the sham+saline group. Previous reports disagree on this issue. Stuck et al\textsuperscript{[25]} reported that the phosphorylation of AMPK decreased 30 min after TAC operation, while in the study by Lei et al\textsuperscript{[26]},

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure5}
\caption{The inhibitory effect of metformin on the protein synthesis pathway is dependent on AMPK activation. (A) Western blot of heart extracts for phosphorylated mTOR, phosphorylated AKT, phosphorylated eEF2, total AKT, total eEF2, and eIF5. Quantitative densitometry for mTOR, AKT, and eEF2 phosphorylation in the WT groups (B) and AMPKα2\textsuperscript{−/−} groups (C). The data are presented as means±SEM of 6 animals per group. In the WT groups, *P<0.05, **P<0.01 vs sham+saline group; †P<0.05 vs TAC+saline group. In the AMPKα2\textsuperscript{−/−} groups, *P<0.05 vs sham+saline group; †P<0.05 vs TAC+saline group.}
\end{figure}
the phosphorylation of AMPK decreased the second week after TAC, followed by a minor increase by the sixth week. In addition, we did not find that a selective deletion of AMPKα2 exacerbated the development of TAC-induced cardiac hypertrophy and LV dysfunction. These results were inconsistent with those of Zhang et al. The reason underlying this discrepancy is not clear; one possible explanation is the degree of aortic constriction by the TAC operation. The wild type mice developed heart failure during the third week after TAC in the work of Zhang et al. However, in the present study, both AMPKα2−/− and WT mice had normal cardiac systolic function after TAC for 6 weeks. Thus, the degree of aortic constriction in the TAC models in the work of Zhang et al. was greater than that of ours.

AMPK is an endogenous protective protein. AMPK may have no or a minor effect on cardioprotection when the heart is subjected to a mild stimulus. This concept was confirmed by transgenic mouse models in which the AMPK gene was deleted or the dominant mutation gene of AMPK was overexpressed. These transgenic mice live without abnormalities. AMPK is activated and plays a role in the cardiac protective response to high-intensity stimulation, as demonstrated by many studies. Thus, we suppose that the induction of AMPK-related cardiac protective activity is significantly related to the stimulus intensity.

**Metformin inhibited signaling pathways that regulate protein synthesis through AMPK activation**

Cardiac hypertrophy involves an increase in protein synthesis. To investigate the mechanism for the antihypertrophic effect of metformin, we measured the activation of AMPK on the signaling pathways that regulate protein synthesis. It was reported that AKT/PKB, an important signaling pathway in regulating protein synthesis, regulates the physiological growth of the heart. Akt1-null mice had a 20% reduction in body size, with a concomitant reduction in heart size. These mice were shown to be defective in exercise-induced cardiac hypertrophy. Sasaki et al. recently reported that metformin and 5-aminoimidazole 4-carboxamide ribonucleotide (AICAR) inhibited the increase in AKT that was induced by pacing. In the present study, we found that TAC induced a significant increase in the phosphorylation of AKT, which was inhibited by metformin in an AMPK-dependent manner. Although it was also reported that Akt1-null mice developed an exacerbated cardiac dysfunction in response to TAC, the decreased phosphorylation of AKT may be involved in the attenuation of hypertrophy.

mTOR can regulate protein synthesis through two pathways. It can activate p70/85 S6 kinase-1 (S6K1) and p54/p56 S6K2, which increase ribosomal biosynthesis and protein translation. It also triggers the release of 4E-binding protein-1 from eIF4E; eIF4E can then bind to other initiation factors such as eIF4G, leading to the initiation of translation. mTOR has been proposed to regulate pathological hypertrophy of the heart. The inhibition of mTOR by rapamycin was found to attenuate pathological cardiac hypertrophy and reverse myocardial dysfunction. Dowling et al. recently reported that metformin inhibited mTOR in a TSC2 and LKB1 dependent manner, which in turn decreased protein synthesis and inhibited cancer cell growth. Another study also demonstrated that metformin inhibited the increase in the phosphorylation of p70s6 kinase induced by phenylephrine *in vitro*. Similarly, we found that the phosphorylation level of mTOR was significantly increased in the TAC group, but almost reversed to a normal state by 6 weeks of metformin treatment. This effect of metformin was not observed in AMPKα2−/− mice, suggesting that the metformin-induced mTOR inhibition was AMPK-dependent. It has also been reported that mTOR could be activated by AKT. Although both AKT and mTOR phosphorylation were increased in TAC-operated mice in our study, whether mTOR was activated by AKT in the TAC model needs further study to be validated.

AMPK activation can lead to an increase in eEF2 phosphorylation, which inhibits the translocation step during elongation. Chan et al. found that metformin and AICAR inhibited the decrease of eEF2 phosphorylation. However, we did not find a significant decrease in eEF2 phosphorylation in TAC-operated mice hearts, and the level of eEF2 phosphorylation was similar in saline- and metformin-treated groups. These data are in agreement with the findings of Zhang et al. Therefore, eEF2 may not be involved in TAC-induced cardiac hypertrophy in mice.

**Conclusion**

Our findings in the present study demonstrate that long-term administration of metformin attenuates cardiac hypertrophy induced by pressure overload in nondiabetic mice. The antihypertrophic effect of metformin may be dependent on AMPK activation. Long-term metformin treatment could therefore be a potential therapy for patients at risk of developing pathological cardiac hypertrophy.

**Acknowledgements**

Professor Benoit VIOLLET (Institute National de la Santé et de la Recherche Médicale U567, Paris, France) kindly provided the AMPKα2-knockout line. This work was supported by the National Natural Science Foundation of China (No 81030001, 30821001) and the Projects of International Cooperation and Exchanges NSFC (No 30910103902).

**Author contribution**

You-yi ZHANG and Han XIAO conceived and designed the experiments. Yong-nan FU, Han XIAO, Xiao-wei MA, and Sheng-yang JIANG performed the experiments. Yong-nan FU and Han XIAO analyzed the data. Yong-nan FU, You-yi ZHANG, Han XIAO, and Ming XU wrote the paper.

**References**

1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854–65.
2 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–89.

3 Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase: development of the energy sensor concept. J Physiol 2006; 574: 7–15.

4 Li YJ, Wang PH, Chen C, Zou MH, Wang DW. Improvement of mechanical heart function by trimetazidine in db/db mice. Acta Pharmacol Sin 2010; 31: 560–9.

5 Arad M, Seidman CE, Seidman JG. AMP-activated protein kinase in the heart: role during health and disease. Circ Res 2007; 100: 474–88.

6 Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167–74.

7 Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 2009; 104: 403–11.

8 Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009; 119: 2568–77.

9 Lorell BH. Transition from hypertrophy to failure. Circulation 1997; 96: 3824–7.

10 Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45–79.

11 Tarnavski O, McMullen JR, Schinke M, Nie Q, Kong S, Izumo S. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol Genomics 2004; 16: 349–60.

12 Wang J, Xu N, Hou N, Zhang J, Cheng X, et al. Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure. Circ Res 2005; 97: 821–8.

13 Chan AT, Soltys CL, Young ME, Proud CG, Dycy JR. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 2004; 279: 32771–9.

14 Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the anti-diabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745–52.

15 Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG 4th, Schlatter U, et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 2004; 279: 43940–51.

16 Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, et al. Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 2006; 130: 2099–112.

17 Snorgaard O, Kober L, Carlsen J. The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. J Intern Med 1997; 242: 407–12.

18 Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFβ1-Smad3 signalling pathway. Cardiovasc Res 2010; 87: 504–13.

19 Rosenkranz S, Fliesh M, Amann K, Laeuserle C, Kilter H, Seeland U, et al. Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1. Am J Physiol Heart Circ Physiol 2002; 283: H1253–62.

20 Schultz JJ, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, et al. TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002; 109: 787–96.

21 Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, et al. Transforming growth factor-β1 function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106: 130–5.

22 Tokuda K, Kai H, Kuwahara F, Yasukawa H, Tahara N, Kudo H, et al. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 2004; 43: 499–503.

23 Tian R, Musi N, D’Agostino J, Hirshman MF, Goodyear LJ. Increased adiponectin monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001; 104: 1664–9.

24 Zhang P, Hu X, Xu X, Fassett J, Zhu G, Viollet B, et al. AMP activated protein kinase-a2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 2008; 52: 918–24.

25 Stuck BJ, Lenski M, Bohm M, Laufs U. Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J Biol Chem 2008; 283: 32562–9.

26 Lei B, Chess DJ, Keung W, O’Shea KM, Lopashchuk GD, Stanley WC. Transient activation of p38 MAP kinase and up-regulation of Fim-1 kinase in cardiac hypertrophy despite no activation of AMPK. J Mol Cell Cardiol 2008; 45: 404–10.

27 Zarrinpashneh E, Beauloye C, Ginion A, Pouleur AC, Havaux X, Hue L, et al. AMPKα2 counteracts the development of cardiac hypertrophy induced by isoproterenol. Biochem Biophys Res Commun 2008; 367: 677–81.

28 Xing Y, Musi N, Fujii N, Zou L, Luptak I, Hirshman MF, et al. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative α2 subunit of AMP-activated protein kinase. J Biol Chem 2003; 278: 28372–7.

29 Russell RR 3rd, Li J, Coven DL, Pyptaert M, Zechner C, Palmeri M, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004; 114: 495–503.

30 Yang J, Holman GD. Insulin and contraction stimulate exocytosis, but increased AMP-activated protein kinase activity resulting from oxidative metabolism stress slows endocytosis of GLUT4 in cardiomyocytes. J Biol Chem 2005; 280: 4070–8.

31 DeBosch B, Treskov I, Lupu TS, Weinheimer C, Kovacs A, Couturios M, et al. Akt1 is required for physiological cardiac growth. Circulation 2006; 113: 2097–104.

32 Heinke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006; 7: 589–600.

33 McMullen JR, Sherwood MC, Tarnavski O, Zang L, Dorfman AL, Shiio T, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004; 109: 3050–5.

34 Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804–12.

35 Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655–7.